Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis

Published:2021-11 Issue:11 Volume:3 Page:1372-1382
ISSN:2589-790X
Container-title:CJC Open
language:en
Short-container-title:CJC Open

Author:

Alhussein Muhammad Mustafa^ORCID,Mokbel Abir,Cosman Tammy,Aghel Nazanin,Yang Eric H.,Mukherjee Som D.,Dent Susan,Ellis Peter M.,Dhesy-Thind Sukhbinder,Leong Darryl P.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

3. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer;Menard;Ann Oncol,2001

4. Targeting HER2 in other tumor types;Scholl;Ann Oncol,2001

5. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries;Corbo;Ann Oncol,2012

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis;Pharmacoepidemiology and Drug Safety;2024-08

2. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;British Journal of Cancer;2024-06-21

3. Breast Cancer Immunotherapy: A Clinical Review for the Plastic Surgeon;Plastic and Reconstructive Surgery - Global Open;2024-06

4. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment;Scientific Reports;2024-05-09

5. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer;Toxicological Research;2024-04-22